AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.390
-0.050 (-3.47%)
At close: Mar 28, 2025, 4:00 PM
1.400
+0.010 (0.72%)
After-hours: Mar 28, 2025, 7:51 PM EDT
AN2 Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AN2 Therapeutics stock have an average target of 3.50, with a low estimate of 2.00 and a high estimate of 5.00. The average target predicts an increase of 151.80% from the current stock price of 1.39.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for AN2 Therapeutics stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +259.71% | Mar 26, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +259.71% | Feb 25, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +259.71% | Feb 3, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +259.71% | Nov 19, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.09
from -1.72
EPS Next Year
-1.07
from -1.09
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | n/a | 76.3M | n/a | |
| Avg | n/a | 37.1M | n/a | |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.91 | -1.01 | -1.23 |
| Avg | -1.09 | -1.07 | -1.19 |
| Low | -1.22 | -1.08 | -1.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.